Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 60760-734

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 60760-734). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60760-734 (Atorvastation 60760 734 30)

Atorvastatin Calcium 40 mg film-coated tablets label showing multiple small label copies with product name, strength, unit count of 30 tablets, and placeholders for lot number and expiration date. Manufactured by Recipharm Pharmaservices Pvt Ltd in India and packaged by St. Mary's Medical Park Pharmacy in Oro Valley, Arizona. The label includes storage instructions to keep at controlled room temperature 15°-30°C (59°-86°F) and states 'USE AS DIRECTED' and 'Rx only.'*

FDA Label Image

Chemical Structure (Chemical Structure)

Chemical structure of atorvastatin calcium dihydrate, illustrating its molecular composition with calcium ion and water of hydration.*

FDA Label Image

Figure 1.jpg (Figure1)

A line graph showing the cumulative incidence percentage over a period of up to 3.5 years comparing Atorvastatin and Placebo. The graph features two lines: a solid line for Atorvastatin and a dashed line for Placebo, with Atorvastatin showing a consistently lower cumulative incidence. The graph includes a hazard ratio (HR) value with confidence intervals and a p-value at the bottom.*

FDA Label Image

Figure 2.jpg (Figure2)

A line graph showing cumulative hazard percentages over time (years) comparing placebo and atorvastatin groups. The x-axis represents time to first primary endpoint through four years of follow-up, and the y-axis shows cumulative hazard percentage. The atorvastatin group shows a lower cumulative hazard compared to placebo, indicated by separate lines and a hazard ratio (HR) provided on the graph.*

FDA Label Image

Figure 3.jpg (Figure3)

A line chart comparing the percentage of subjects experiencing an event over time (years) for Atorvastatin 10 mg and Atorvastatin 80 mg dosages. The x-axis represents time to first major cardiovascular endpoint in years, and the y-axis shows the percentage of subjects experiencing the event, with Atorvastatin 80 mg showing a lower event rate than 10 mg over 5 years.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.